Precursory regulatory cytotrophoblast cells and uses thereof
AssigneeAccelerated Biosciences Corp.
InventorsJau-Nan Lee, Yuta Lee, Tony Tung-Yin Lee
Life of this patent
Estimating the term…
Abstract
Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Disclosed herein are isolated populations of precursory regulatory cytotrophoblast cells, where the cells are produced in vitro. Disclosed herein are genetically engineered cells. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
Claims20
A pharmaceutical composition comprising an isolated, genetically engineered precursory regulatory cytotrophoblast cell (prCTB) and an acceptable carrier, wherein:
- (i) the genetically-engineered prCTB expresses beta-hormone human chorionic gonadotropin (β-hCG), human leukocyte antigen G (HLA-G), CD56, insulin, heat shock protein 90 (HSP90), CD4, CD16, CD107a, CD8, interleukin 15 (IL-15), leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1), leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), T cell receptor (TCR), killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4), programmed death-ligand 1 (PD-L1), apoptosis signal receptor (Fas), Fas Ligand (FasL), CD335 (NKp46), CD11b, CD49f, CD3, CD19, CD34, or any combination thereof;
- and
- (ii) the genetically-engineered prCTB expresses p53, Ki67, glutamate decarboxylase (GAD65), heat shock protein 70 (HSP70), soluble CD40-ligand (sCD40L), B cell leukemia/lymphoma 2 related protein A1 (BCL2A1 or Bfl-1), myeloid cell leukemia sequence 1 (Mcl-1), or any combination thereof;
- and
- wherein the acceptable carrier is buffered saline.
A pharmaceutical composition comprising an isolated population of cells comprising genetically-engineered precursory regulatory cytotrophoblasts (prCTBs) and an acceptable carrier, wherein:
- (i) at least 10% of the population expresses CD16 and CD56;
- (ii) at least 2% of the population expresses CD4;
- (iii) at least 2% of the population expresses CD8;
- (iv) at least 5% of the population expresses CD107;
- or
- (v) any combination thereof;
- and
- wherein the acceptable carrier is buffered saline.
Dependencies are inferred from the claim text.